Collegium Pharmaceuticals is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The company was founded in 2002 and is based in Canton, Massachusetts.
COLL Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Collegium Pharmaceutical Inc. To summarize, we found that Collegium Pharmaceutical Inc ranked in the 17th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Collegium Pharmaceutical Inc ended up being:
The company's debt burden, as measured by earnings divided by interest payments, is -2.69 -- which is good for besting only 17.13% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
The company's compound free cash flow growth rate over the past 1.25 years comes in at -0.15%; that's greater than just 12.6% of US stocks we're applying DCF forecasting to.
The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than only 11.42% of the free cash flow producing stocks we're observing.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Collegium Pharmaceutical Inc? See AMPH, HAE, CNMD, GMED, and QGEN.